# (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

> **NCT02561988** · PHASE1 · COMPLETED · sponsor: **Blueprint Medicines Corporation** · enrollment: 86 (actual)

## Conditions studied

- Aggressive Systemic Mastocytosis
- Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
- Mast Cell Leukemia
- Relapsed or Refractory Myeloid Malignancies

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT02561988
- **Lead sponsor:** Blueprint Medicines Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-10
- **Primary completion:** 2022-10-05
- **Final completion:** 2023-01-19
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561988, "(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02561988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*